Listed pharmaceuticals ‘increase’ R&D investments, but ‘decrease’ its ratios to sales
Although the 3rd quarter’s collective R&D expenses of listed pharmaceutical companies increased this year compared with the same quarter of the last year, the average ratio to sales was decreased in the KOSPI and KOSDAQ both.
In each category, companies with the 3rd quarter’s largest R&D expense...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
